ScientiaCME A clear-eyed view of the path forward advanced renal cell carcinoma (RCC) treatment

Details

In this online, self-learning activity:

Renal cell carcinoma (RCC) is a cancer that develops in the nephrons. It is responsible for most cancers of the kidney and renal pelvis, which occur in close to 82,000 people and account for over 14,000 deaths in the U.S. annually. The five-year survival rate is 93% for patients with early stages of the disease. However, in patients with advanced or metastatic disease, the five-year survival is 17%, representing an area of ongoing clinical need.

Topics Covered

Faculty introduction, disclosures

Introductory content and review of advanced RCC

· Statistics, prognosis
· Healthcare burden

Treatment considerations for advanced RCC, including guideline-based approaches and clinical trial evidence

· Goals of therapy
· Factors impacting decision-making: favorable vs. intermediate- or poor-risk advanced RCC, eligibility for immunotherapy
· Present treatment approaches

Clear cell advanced RCC

– Initial therapy

· Preferred: immunotherapy and/or tyrosine kinase inhibition
· Additional options

– Assessment of response

– Next-line therapies, with considerations including: prior therapy and patient suitability/tolerance

Non-clear cell advanced RCC, including less common types

· Emerging strategies and therapies
· Treatment challenges, gaps in care

Adverse effect identification and management

Gaps in care

· Patient case(s)

Summary, conclusions, and best practice recap

Learning Objectives

By the end of the session the participant will be able to:

• Recall the pathophysiology of advanced RCC such that it informs treatment mechanisms.
• Describe: present and emerging treatment options for advanced RCC; their place or anticipated place in therapy; and risk-benefit profiles.
• Formulate a treatment plan for a patient with advanced RCC.

Target Audience

HCPs including but not limited to: medical oncologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and any other HCPs with an interest in or who clinically encounter patients with RCC.

Additional credit info

ACCME Activity #203272118

ScientiaCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: ScientiaCME designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ toward the AMA Physician’s Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

ABIM MOC Credit Type: Medical Knowledge

Physicians: For maintenance of certification (MOC) points, you must enter your board certification ID # and birth date correctly.  It is the learner’s responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive MOC points for this activity. By providing this data, you acknowledge that it will be shared with ACCME and the applicable certifying board. Please note: Not all activities on this site provide MOC points. If this activity does not specify that it provides MOC points in this section, then it does NOT provide MOC points. This activity provides MOC points only for ABIM.

Pharmacists

ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours  of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit. ACPE #0574-0000-25-013-H01-P. This is an Application (A)-type activity. 

Pharmacists: You must enter your NABP # and birth date correctly so that proof of participation can be posted to your NABP CPE profile. It is the learner’s responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive CPE credit for this activity.

Nurses: The American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. This activity is designated for up to 1.0 AMA PRA Category 1 Credit(s)™.

Physician Assistants: The American Academy of Physician Assistants (AAPA) accepts AMA PRA Category 1 Credit™ assigned by organizations accredited by the ACCME as satisfying Category 1 CME for National Commission on Certification of Physician Assistants (NCCPA) national certification maintenance. This activity is designated for up to 1.0 AMA PRA Category 1 Credit(s)™.

Nurse Practitioners: The American Academy of Nurse Practitioners Certification Board (AANPCB) states that continuing education providers accredited by the ACCME may provide acceptable, accredited Advanced Practice Provider content. This activity is designated for up to 1.0 AMA PRA Category 1 Credit(s)™.